![]() |
市場調査レポート
商品コード
1576923
脳深部刺激装置の世界市場:洞察、競合情勢、市場予測:2030年Deep Brain Stimulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
||||||
カスタマイズ可能
適宜更新あり
|
脳深部刺激装置の世界市場:洞察、競合情勢、市場予測:2030年 |
出版日: 2024年10月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
脳深部刺激装置(DBS)の市場規模は、2023年に13億1,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に10.40%のCAGRで拡大し、2030年には23億7,000万米ドルに達すると予測されています。脳深部刺激療法(DBS)装置の需要は、パーキンソン病やてんかんなどの神経疾患の有病率の上昇により伸びています。これらの疾患に罹患しやすい高齢者人口の増加が、この動向を後押しする大きな要因となっています。さらに、研究開発(R&D)への注力と製品イノベーションにおける技術進歩の高まりが、2024年から2030年までの予測期間における脳深部刺激装置市場のプラス成長に大きく寄与しています。
DBS技術におけるこうした進歩は、神経疾患に対する治療の精度、安全性、有効性を向上させることを目的としています。その結果、治療の選択肢としてDBSを選択する患者が増え、市場の拡大を後押ししています。
脳深部刺激装置(DBS)市場は、パーキンソン病、ジストニア、振戦などのさまざまな運動障害の有病率の上昇により成長を遂げています。2021年2月の英国議会のデータによると、英国では約145,000人の成人がパーキンソン病を患っており、この数は2030年までに172,000人に達すると予想されています。同様に、パーキンソン財団は2022年に、米国では毎年約9万人がパーキンソン病(PD)と診断されていると報告しており、予測では2030年までにPD罹患者数は120万人に達するとされています。その結果、PDの症状を緩和するために標的を絞った神経刺激を提供するDBS装置の需要が大幅に増加し、市場成長の原動力になると予想されます。
当レポートでは、世界の脳深部刺激装置市場について調査し、市場の概要とともに、製品タイプ別、バッテリータイプ別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。
Deep Brain Stimulation Devices Market by Product Type (Single Channel and Dual Channel), Battery Type (Rechargeable and Non-Rechargeable), Application (Parkinson's Disease, Epilepsy, Obsessive Compulsive Disorder, Dystonia, and Others), End-User (Hospitals and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence of neurological disorders and technological advancements in DBS devices
The deep brain stimulation devices (DBS) Market was valued at USD 1.31 billion in 2023, growing at a CAGR of 10.40% during the forecast period from 2024 to 2030 to reach USD 2.37 billion by 2030. The demand for deep brain stimulation (DBS) devices is experiencing growth due to the increasing prevalence of neurological disorders, such as Parkinson's disease and epilepsy. The rising geriatric population, which is more susceptible to these disorders, is a major factor driving this trend. Additionally, the growing focus on research and development (R&D) and technological advancements in product innovation are contributing significantly to the positive growth of the deep brain stimulation devices market during the forecast period from 2024 to 2030.
These advancements in DBS technology are aimed at improving the precision, safety, and efficacy of treatments for neurological conditions. As a result, more patients are turning to DBS as a therapeutic option, boosting market expansion.
Deep Brain Stimulation Devices Market Dynamics:
The deep brain stimulation (DBS) devices market is experiencing growth due to the rising prevalence of various movement disorders such as Parkinson's disease, dystonia, and tremors. According to data from the UK Parliament in February 2021, approximately 145,000 adults in the United Kingdom were living with Parkinson's disease, with this number expected to reach 172,000 by 2030. Similarly, the Parkinson's Foundation reported in 2022 that around 90,000 individuals are diagnosed with Parkinson's disease (PD) annually in the United States, and projections suggest that the number of people affected by PD will reach 1.2 million by 2030. As a result, the demand for DBS devices, which provide targeted neural stimulation to alleviate PD symptoms, is expected to increase significantly, driving market growth.
In addition to Parkinson's disease, the growing prevalence of epilepsy is also fueling global demand for DBS devices. According to the World Health Organization (WHO), approximately 50 million people worldwide were affected by epilepsy in 2023. The WHO estimates that around 5 million new cases of epilepsy are diagnosed annually, making it the most common neurological disorder globally. DBS devices have proven to be effective in controlling seizure occurrences, further propelling growth in the DBS market.
Key market players are actively developing innovative devices to address the increasing prevalence of movement disorders, contributing to substantial market expansion. For example, in January 2024, Abbott Laboratories received FDA approval for its Liberta RC(TM) DBS system. Notably, Liberta is the smallest rechargeable DBS device available, featuring remote programming capabilities, and designed specifically for treating conditions such as Parkinson's disease and essential tremors. The rise in research and development activities focused on DBS devices is expected to positively influence the market's growth during the forecast period.
However, the high cost of these devices and the risk of device-associated complications remain key challenges that could limit the growth of the deep brain stimulation devices market.
Deep Brain Stimulation Devices Market Segment Analysis:
Deep Brain Stimulation Devices Market by Product Type (Single Channel and Dual Channel), Battery Type (Rechargeable and Non-Rechargeable), Application (Parkinson's disease, Epilepsy, Obsessive Compulsive Disorder, Dystonia, and Others), End-User (Hospitals and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the deep brain stimulation (DBS) devices market, dual-channel DBS systems are expected to account for a prominent market share during the forecast period. This growth is driven by the rising number of patients affected by neurological conditions such as essential tremors and obsessive-compulsive disorders. According to the National Tremor Foundation, over one million individuals in the United Kingdom and 10 million in the United States were diagnosed with essential tremors in 2021. Dual-channel DBS systems, which effectively stimulate the ventral intermediate nucleus (VIM) of the thalamus, play a crucial role in significantly reducing tremors in both upper and lower limbs. The increasing prevalence of neurological conditions is fueling demand for dual-channel DBS devices, thereby driving market growth.
One of the key advantages of dual-channel neurostimulators is their ability to provide bilateral therapy through two separate stimulation channels. This innovative design allows for fewer incisions and minimizes the need for extensive tunneling of extensions compared to single-channel DBS systems, leading to a less invasive surgical procedure. These benefits are anticipated to increase the demand for dual-channel DBS devices throughout the forecast period, contributing significantly to the overall expansion of the DBS devices market.
Key market players are heavily focused on research and development to create advanced dual-channel DBS devices, aiming to strengthen their competitive position. For example, in January 2024, Medtronic received FDA approval for its Percept(TM) RC DBS system. This innovative device features sensing technology that enables physicians to tailor treatments more precisely for patients with movement disorders such as Parkinson's disease, essential tremor, dystonia, and epilepsy. Such advancements in product development are expected to drive significant growth in the dual-channel DBS segment, further boosting the overall deep brain stimulation devices market.
North America is expected to dominate the overall deep brain stimulation devices market:
North America is expected to account for the largest market share in the deep brain stimulation (DBS) devices market in 2023. This growth is driven by the rising prevalence of movement disorders such as Alzheimer's disease, tremors, and obsessive-compulsive disorder (OCD). The increasing geriatric population, along with favorable government support and initiatives focused on brain health, are key factors contributing to the expansion of the DBS devices market in the region. Additionally, technological advancements in product development are further accelerating market growth.
The growing prevalence of neurological disorders is a significant factor driving the demand for DBS devices in North America. According to a report from the Centers for Disease Control and Prevention (CDC) published in September 2023, approximately 6.7 million individuals aged 65 and older were living with Alzheimer's disease in the United States, with this number projected to reach 13.9 million by 2060. DBS devices regulate neuronal activity in specific areas of the brain, helping improve neural function and alleviate cognitive decline. As the number of neurological disorder cases continues to rise, the demand for DBS devices is expected to increase, further driving market growth in the region.
The expanding geriatric population is another factor contributing to the growth of the DBS market. Older adults are particularly vulnerable to neurological disorders due to age-related nerve degeneration. According to the Population Reference Bureau, approximately 58 million individuals aged 65 and older were living in the United States in 2022, and this number is projected to reach 82 million by 2050. Movement disorders like Parkinson's disease are more common among this age group due to irregular brain activity, making the growing elderly population a key driver for DBS device demand.
Epilepsy also represents a significant driver of demand for DBS devices. According to the CDC, approximately 3 million people in the United States were living with epilepsy in 2021. The increasing number of epilepsy cases has encouraged key players in the industry to develop DBS devices specifically for treating epilepsy. For instance, in February 2022, Precisis GmbH received FDA Breakthrough Device Designation for its EASEE system, which delivers precise electrical currents to targeted areas of the brain to control seizures. Designed for individualized brain stimulation, the system is placed above the origin of epileptic seizures, significantly improving treatment outcomes. These developments are contributing to the growth of the DBS devices market in the region.
Government support is another critical factor boosting market growth. In March 2023, the Government of Canada announced an investment of CAD 38.3 million for the Brain Health Research Initiative, aimed at advancing research on aging brains and reducing the risks of dementia and cognitive impairment. This initiative also focuses on improving care and services for individuals affected by cognitive decline. Such government-backed initiatives are expected to further foster market growth in North America.
In summary, the rising prevalence of movement disorders, increasing government support, and technological innovations in product development are key factors driving the growth of the deep brain stimulation devices market in North America.
Deep Brain Stimulation Devices Market Key Players:
Some of the key market players operating in the deep brain stimulation devices market include Abbott Laboratories, Medtronic, Boston Scientific Corporation, Aleva Neurotherapeutics, Renishaw plc, NeuroPace, Inc., NeuroSigma, Inc., Elekta, LivaNova PLC, SceneRay Co., Ltd., Synapse Biomedical, BrainsWay, Magstim, Newronika S.p.A., Brainlab AG, Functional Neuromodulation, Ltd., Theranica Bio-Electronics Ltd., Precisis GmbH, Neuros Medical, Magnus Medical, Inc., and others.
Recent Developmental Activities in the Deep Brain Stimulation Devices Market:
Key Takeaways from the Deep Brain Stimulation Devices Market Report Study
Target Audience who can be benefited from this Deep Brain Stimulation Devices Market Report Study
Frequently Asked Questions for the Deep Brain Stimulation Devices Market: